tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2013 May 1. [Epub ahead of print]
MDCK cell culture-derived formalin-inactivated influenza whole virion vaccine from an influenza virus library conferred cross-protective immunity by intranasal administration in mice.
Haredy AM, Takenaka N, Yamada H, Sakoda Y, Okamatsu M, Yamamoto N, Omasa T, Ohtake H, Mori Y, Kida H, Yamanishi K, Okamoto S.
Source
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan.
Abstract
It is so far impossible to predict the next pandemic influenza virus strain. We have thus established a library of influenza viruses of all the hemagglutinin and neuraminidase subtypes and their genes. In this article we examine the applicability of a rapid production model for the preparation of vaccines against the emergence of pandemic influenzas. This procedure utilizes the influenza virus library, cell culture-based vaccine production, and intranasal administration to induce a cross-protective immune response. First, an influenza virus reassortant from the library, A/duck/Hokkaido/Vac-3/2007 (H5N1), was passaged 22 times (P22) in Madin-Darby canine kidney (MDCK) cells. The P22 virus had a titer of more than 2 ?108 plaque-forming units/ml, which was 40 times that of the original strain, with 4 point mutations, which altered amino acids in the deduced protein sequences encoded by the PB2 and PA genes. We then produced a formalin-inactivated whole virion vaccine from the MDCK-cell cultured A/duck/Hokkaido/Vac-3/2007 (H5N1) P22. The intranasal immunization of mice with this vaccine protected them against the challenge with lethal influenza viruses of homologous and heterologous subtypes. We further demonstrated that intranasal immunization with the vaccine induced a cross-reactive neutralizing antibody response against the homotypic H5N1 influenza virus and its antigenic variants, and cross-reactive cell-mediated immune responses to the homologous virus, its variants within an intrasubtype, and even to an influenza virus of a different subtype. These results indicate that a rapid model for emergency vaccine production may be effective for producing the next generation of pandemic influenza vaccines.
PMID:
23637045
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23637045
MDCK cell culture-derived formalin-inactivated influenza whole virion vaccine from an influenza virus library conferred cross-protective immunity by intranasal administration in mice.
Haredy AM, Takenaka N, Yamada H, Sakoda Y, Okamatsu M, Yamamoto N, Omasa T, Ohtake H, Mori Y, Kida H, Yamanishi K, Okamoto S.
Source
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan.
Abstract
It is so far impossible to predict the next pandemic influenza virus strain. We have thus established a library of influenza viruses of all the hemagglutinin and neuraminidase subtypes and their genes. In this article we examine the applicability of a rapid production model for the preparation of vaccines against the emergence of pandemic influenzas. This procedure utilizes the influenza virus library, cell culture-based vaccine production, and intranasal administration to induce a cross-protective immune response. First, an influenza virus reassortant from the library, A/duck/Hokkaido/Vac-3/2007 (H5N1), was passaged 22 times (P22) in Madin-Darby canine kidney (MDCK) cells. The P22 virus had a titer of more than 2 ?108 plaque-forming units/ml, which was 40 times that of the original strain, with 4 point mutations, which altered amino acids in the deduced protein sequences encoded by the PB2 and PA genes. We then produced a formalin-inactivated whole virion vaccine from the MDCK-cell cultured A/duck/Hokkaido/Vac-3/2007 (H5N1) P22. The intranasal immunization of mice with this vaccine protected them against the challenge with lethal influenza viruses of homologous and heterologous subtypes. We further demonstrated that intranasal immunization with the vaccine induced a cross-reactive neutralizing antibody response against the homotypic H5N1 influenza virus and its antigenic variants, and cross-reactive cell-mediated immune responses to the homologous virus, its variants within an intrasubtype, and even to an influenza virus of a different subtype. These results indicate that a rapid model for emergency vaccine production may be effective for producing the next generation of pandemic influenza vaccines.
PMID:
23637045
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23637045